Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Michaelis

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Leukemia Research|May 23, 2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world studyGemlyn George, Alexandra Rezazadeh, Felicia Zook, et al.
Pharmacotherapy|October 31, 2012
Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changesKevin T Stroupe, Elizabeth Tarlov, Todd A Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Cancers|March 13, 2024
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 TrialScott R Solomon, Bayard L Powell, Jamie Koprivnikar, et al.
The Lancet. Haematology|March 31, 2019
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 studyMichael R Savona, Olatoyosi Odenike, Philip C Amrein, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|January 28, 2026
One academic health center's response to a freedom of expression controversyJohn R Raymond, Laura C Michaelis, Adrienne B Mitchell, et al.
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
Leukemia|February 15, 2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemiaSameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, et al.
Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Leukemia Research|May 23, 2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world studyGemlyn George, Alexandra Rezazadeh, Felicia Zook, et al.
Pharmacotherapy|October 31, 2012
Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changesKevin T Stroupe, Elizabeth Tarlov, Todd A Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Cancers|March 13, 2024
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 TrialScott R Solomon, Bayard L Powell, Jamie Koprivnikar, et al.
The Lancet. Haematology|March 31, 2019
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 studyMichael R Savona, Olatoyosi Odenike, Philip C Amrein, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|January 28, 2026
One academic health center's response to a freedom of expression controversyJohn R Raymond, Laura C Michaelis, Adrienne B Mitchell, et al.
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
Leukemia|February 15, 2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemiaSameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, et al.
Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
Pageof 6